-
A new drug for the treatment of neurogenic orthostatic hypotension (NOH) has been approved by the FDA under its accelerated approval program. Droxidopa is a prodrug to norepinephrine.
-
The consequences of vitamin b12 (B12) deficiency most commonly include neurologic (CNS and peripheral nervous system) and hematologic (megaloblastic anemia).
-
Curcumin, the primary active constituent of curcuma longa, is well known for its antioxidative and anti-inflammatory actions, but also has been used traditionally for conditions including depression and anxiety in Chinese and Ayurvedic medicine
-
In a survey of consecutive myeloma patients from the Mayo Clinic on hypothetical constructs with varying expectations regarding overall survival benefit, toxicity, and financial burden, it was found that the majority of patients would not choose maintenance if toxicity was more than just mild and overall survival benefit was less than 1 year. Increasing financial burden (drug cost) also reduced the numbers that would choose maintenance therapy. Males were more likely than females to choose treatment in each of the scenarios presented.
-
Inhaled apomorphine, at doses up to 0.8 mg, appears safe and well tolerated by patients with Parkinsons disease, but does not result in significant improvement in wearing off periods, at the tested doses.
-
The use of dabigatran in patients with mechanical heart valves compared with patients receiving warfarin was associated with increased rates of thromboembolic and bleeding complications, thus demonstrating no benefit and an excess risk.
-
In a study of men in the Veterans Affairs health care system with low serum testosterone levels, the use of testosterone therapy was associated with an increased risk of mortality, myocardial infarction, or ischemic stroke.
-
-
Historically, men with high-risk prostate cancer were believed to have low survival rates after definitive treatment with either surgery or radiation. However, long-term results of dose-escalated radiotherapy of doses ≥ 75.6 Gy, along with long-term androgen deprivation therapy (ADT), demonstrate 5-year survival rate of 92%, 5-year biochemical control rate of 82%, and symptomatic local failure rate of 0%. Death from prostate cancer was only 5.5% at 10 years in men treated with high-dose radiation therapy and ADT.
-